Home Cart Sign in  
Chemical Structure| 15400-54-1 Chemical Structure| 15400-54-1

Structure of 15400-54-1

Chemical Structure| 15400-54-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 15400-54-1 ]

CAS No. :15400-54-1
Formula : C7H10N4O2
M.W : 182.18
SMILES Code : O=C(C1=CN=C(N)N=C1N)OCC
MDL No. :MFCD04973411
InChI Key :MANFWSKJPOXKJZ-UHFFFAOYSA-N
Pubchem ID :222669

Safety of [ 15400-54-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 15400-54-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.29
Num. rotatable bonds 3
Num. H-bond acceptors 4.0
Num. H-bond donors 2.0
Molar Refractivity 46.93
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

104.12 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.38
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.28
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.17
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.41
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.37
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.14

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.29
Solubility 9.36 mg/ml ; 0.0514 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.03
Solubility 1.71 mg/ml ; 0.00937 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.42
Solubility 6.99 mg/ml ; 0.0384 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.21 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.98

Application In Synthesis of [ 15400-54-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 15400-54-1 ]

[ 15400-54-1 ] Synthesis Path-Downstream   1~8

  • 1
  • [ 15400-54-1 ]
  • [ 99419-22-4 ]
  • 2
  • [ 876489-95-1 ]
  • [ 15400-54-1 ]
  • 3
  • [ 71406-78-5 ]
  • [ 15400-54-1 ]
YieldReaction ConditionsOperation in experiment
42% Preparation 14 Synthesis of 2,4-diamino 5-carbethoxy pyrimidine 5.88g(27.6 mmol) of 4-amino 5-carbethoxy 2-thiomethylpyrimidine was dissolved in 60mlitre of dichloromethane and the solution was cooled down to 0C. To this solution was slowly added dropwise 11.4g(1.2 equivalents, ~50%) of metachloroperbenzoic acid dissolved in 40mlitre of dichloromethane. The reaction was performed for 2 hours at 0C and then, stopped with 5% of sodium thiosulfate solution. The reaction mixture was washed with sodium hydrogen carbonate solution and concentrated by distillation under reduced pressure. To this concentrate was added 100mlitre of 28% aqueous ammonium solution and the mixture was stirred for 2 hours at room temperature. This mixture was neutralized with acetic acid and then, filtered and dried to obtain 2g(yield: 42%) of the title compound as solid. 1H NMR(DMSO) delta 1.25(t, 3H), 4.19(q, 2H), 7.23(s, 1H), 7.38(s, 1H), 7.45(s, 1H) Mass(FAB, m/e): 183
  • 5
  • 2-ethylsulfanyl-4-amino-pyrimidine-carboxylic acid-(5)-ethyl ester [ No CAS ]
  • [ 15400-54-1 ]
  • 6
  • [ 15400-54-1 ]
  • [ 98024-82-9 ]
  • 7
  • [ 51940-64-8 ]
  • [ 15400-54-1 ]
  • 8
  • [ 28485-17-8 ]
  • [ 15400-54-1 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 15400-54-1 ]

Esters

Chemical Structure| 65195-35-9

A118296 [65195-35-9]

Ethyl 4-aminopyrimidine-5-carboxylate

Similarity: 0.90

Chemical Structure| 57401-76-0

A218468 [57401-76-0]

Ethyl 2-aminopyrimidine-5-carboxylate

Similarity: 0.86

Chemical Structure| 20187-46-6

A658907 [20187-46-6]

Ethyl 4-amino-2-hydroxypyrimidine-5-carboxylate

Similarity: 0.84

Chemical Structure| 308348-93-8

A174185 [308348-93-8]

Methyl 2-aminopyrimidine-5-carboxylate

Similarity: 0.83

Chemical Structure| 15400-53-0

A107500 [15400-53-0]

Ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate

Similarity: 0.80

Amines

Chemical Structure| 65195-35-9

A118296 [65195-35-9]

Ethyl 4-aminopyrimidine-5-carboxylate

Similarity: 0.90

Chemical Structure| 57401-76-0

A218468 [57401-76-0]

Ethyl 2-aminopyrimidine-5-carboxylate

Similarity: 0.86

Chemical Structure| 20187-46-6

A658907 [20187-46-6]

Ethyl 4-amino-2-hydroxypyrimidine-5-carboxylate

Similarity: 0.84

Chemical Structure| 20737-41-1

A168632 [20737-41-1]

4-Aminopyrimidine-5-carboxylic acid

Similarity: 0.83

Chemical Structure| 308348-93-8

A174185 [308348-93-8]

Methyl 2-aminopyrimidine-5-carboxylate

Similarity: 0.83

Related Parent Nucleus of
[ 15400-54-1 ]

Pyrimidines

Chemical Structure| 65195-35-9

A118296 [65195-35-9]

Ethyl 4-aminopyrimidine-5-carboxylate

Similarity: 0.90

Chemical Structure| 57401-76-0

A218468 [57401-76-0]

Ethyl 2-aminopyrimidine-5-carboxylate

Similarity: 0.86

Chemical Structure| 20187-46-6

A658907 [20187-46-6]

Ethyl 4-amino-2-hydroxypyrimidine-5-carboxylate

Similarity: 0.84

Chemical Structure| 20737-41-1

A168632 [20737-41-1]

4-Aminopyrimidine-5-carboxylic acid

Similarity: 0.83

Chemical Structure| 308348-93-8

A174185 [308348-93-8]

Methyl 2-aminopyrimidine-5-carboxylate

Similarity: 0.83